PMV Pharmaceuticals Reports Q3 Loss, Cash Position

The clinical-stage drug developer posted a wider third-quarter net loss after closing a $50 million public offering in August.

Updated on Nov. 10, 2026 in Corporate Finance

Bold flat-color vector editorial illustration of white pharmaceutical tablets in a glass dish beside a brass weight, evoking drug-development financing.
PMV Pharmaceuticals posted a wider third-quarter net loss of $34.4 million, driven largely by a $12.8 million non-cash warrant charge, while extending its cash runway into 2028. AI Illustration. Upload story photo >

PMV Pharmaceuticals reported third quarter 2026 financial results, ending the period with $108.5 million in cash, cash equivalents, and marketable securities. The company posted a net loss of $34.4 million for the quarter, up from $21.1 million a year earlier.

Why it matters

The wider loss was driven largely by a $12.8 million non-cash charge tied to the fair value of a common stock warrant liability, not by operating spending alone. The company says its cash runway now extends into the first quarter of 2028, giving it time to advance its lead program.

Cash, equivalents and marketable securities totaled $108.5 million at September 30, 2026, down from $112.9 million at December 31, 2025, while net cash used in operations was $52.4 million over nine months. The $12.8 million non-cash warrant loss is a valuation adjustment and its future direction remains unresolved.

The players

PMV Pharmaceuticals

A clinical-stage precision oncology company headquartered in Princeton, New Jersey, developing targeted cancer therapies.

Matt Eckler, Ph.D.

A life sciences investor at Samsara BioCapital who was appointed to PMV Pharmaceuticals' Board of Directors.

The details

The company said its R&D expenses were $16.1 million and G&A expenses were $4.0 million for the quarter. R&D spending fell mainly because of lower contract research organization costs for the rezatapopt program, while G&A declined on lower finance and legal support costs.

Timeline

  1. December 31, 2025: Baseline date for the cash comparison.

  2. August 2026: The company closed a $50 million public offering.

  3. September 30, 2026: The third quarter ended.

  4. First quarter of 2027: The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer.

  5. First quarter of 2028: Expected end of the company's cash runway.

Market Dynamics

The planned New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer, slated for the first quarter of 2027, is the program's next major regulatory milestone. Its timing determines whether the company's cash runway into early 2028 can support the step from clinical data to market approval.

Shareholders should weigh the company's cash runway into early 2028 against the scheduled regulatory filing in early 2027. The non-cash warrant charge can swing reported losses without reflecting day-to-day spending.

The takeaway

Investors tracking early-stage drug developers should watch whether non-cash valuation swings continue to distort reported losses. The first-quarter 2027 filing will show whether the runway assumption holds.

What happens next

The company plans to submit a New Drug Application for rezatapopt in the first quarter of 2027.

Further reading

Explore more corporate finance coverage for context on how biotech companies manage cash runways and offerings.

More information

Review the PYNNACLE Phase 1/2 trial registry entry for details on the study underlying the company's pipeline.

Source note: This article includes information reported by The Manila times.